1. Executive Summary
1.1 Sector Highlights
1.2 Overview of Chapter Content
1.3 Research and Analysis Methods
1.4 Glossary of Terms Related to Medical Devices
2. An Introduction to the Medical Device Industry
2.1 Classification of Medical Devices
2.1.1 The US Classification System
2.1.2 The European Classification System
2.2 Regulation of Medical Devices
2.2.1 The US Approval and Regulation System
2.2.2 European Approval and Regulation Systems
2.2.2.1 Post-marketing Surveillance in the EU
2.3 Coronary Artery Disease and Coronary Stents
2.3.1 Bare Metal Stents
2.3.2 Drug Eluting Stents (DES)
2.3.3 Drugs Used in DES
2.3.3.1 Sirolimus
2.3.3.2 Everolimus
2.3.3.3 Zotarolimus
2.3.3.4 Paclitaxel
2.4 Neuromodulation
2.4.1 Chronic Pain and Spinal Cord Stimulation
2.4.2 Parkinson's Disease and Deep Brain Stimulation
2.4.2.1 Parkinson's Disease
2.4.2.2 Deep Brain Stimulation
2.4.3 Epilepsy and Vagus Nerve Stimulation
3. The Global Medical Device Market, 2010-2025
3.1 Medical Devices: Market Overview
3.1.1 Size of the Medical Device Market in 2009
3.1.2 Medical Device Market: Revenue Analysis by Company, 2009
3.1.2.1 Johnson & Johnson
3.1.2.2 Siemens Healthcare
3.1.2.3 GE Healthcare
3.1.2.4 Medtronic
3.1.2.5 Baxter International
3.1.2.6 Philips Healthcare
3.1.2.7 Roche
3.1.2.8 Abbott Laboratories
3.1.2.9 Boston Scientific Corp
3.1.2.10 Becton, Dickinson & Co
3.1.2.11 Samsung: A New Entry into the Market
3.2 World Medical Device Market Forecast, 2010-2015
3.3 World Medical Device Market Forecast, 2015-2025
3.4 Regional Medical Device Market Forecasts, 2010-2025
3.4.1 The Market in the US, Europe and Japan
3.4.1.1 The US Market
3.4.1.2 European Markets
3.4.1.3 The Japanese Market
3.4.2 The Chinese and Indian Markets
3.4.2.1 China
3.4.2.2 India
4. Issues Affecting the Medical Device Market
4.1 SWOT Analysis of the Medical Device Industry and Market, 2010-2025
4.2 Strengths
4.2.1 Large Number of Participating Companies
4.2.2 New Market Sectors are Growing Rapidly
4.3 Weaknesses
4.3.1 The Market is Susceptible to Economic Pressures
4.3.2 Much of the Industry Has Reached Maturity
4.4 Opportunities
4.4.1 The Potential of Personalised Medicine
4.4.2 An Aging Global Population
4.4.3 Rapid Growth in Emerging Markets
4.4.4 Increased Incidence and Prevalence of Many Diseases
4.5 Threats
4.5.1 US Medical Devices Excise Tax
4.5.2 Changes to Reimbursement Globally
4.5.3 Comparative Effectiveness Research
5. Cardiovascular & Cardiology Device Market
5.1 Cardiovascular & Cardiology Devices: Market Overview
5.1.1 Cardiovascular & Cardiology Device Market in 2009
5.1.2 Cardiovascular & Cardiology Device Market Forecast, 2010-2025
5.2 The Drug Eluting Coronary Stent Market, Analysis & Forecast, 2010-2025
5.2.1 The DES Market, 2009
5.2.2 The DES Market Forecast, 2010-2015
5.2.3 The DES Market Forecast, 2015-2025
5.3 Leading Coronary Stent Product Analysis
5.3.1 Cypher Sirolimus-Eluting Stent (Cordis)
5.3.2 Taxus Paclitaxel-Eluting Stent (Boston Scientific)
5.3.2.1 Disputes Over Paclitaxel-Eluting Stents
5.3.3 Promus Everolimus-Eluting Stent (Boston Scientific)
5.3.4 Xience V Everolimus-Eluting Stent (Abbott Vascular)
5.3.5 Endeavor (Medtronic)
5.3.6 BioMatrix (Biosensors International)
5.4 Coronary Stent Pipeline
5.4.1 Jactax (Boston Scientific)
5.4.2 MiStent (MiCell Technologies)
5.4.3 Synergy (Boston Scientific)
5.4.4 Nevo (Cordis)
5.4.5 BioFreedom (Biosensors International)
5.4.6 VESTAsync (MIV Therapeutics)
5.4.7 Catania (CeloNova BioSciences)
5.4.8 Genous Combo (OrbusNeich)
5.4.9 Bioabsorbable Stents
5.5 SWOT Analysis of the DES Industry, 2010-2025
5.5.1 Strengths
5.5.1.1 DES Are More Effective than BMS
5.5.1.2 Continuous Innovation
5.5.1.3 Continuously-Evolving Market
5.5.2 Weaknesses
5.5.2.1 Stent Thrombosis
5.5.2.2 The Success of DES Compared with Other Treatments
5.5.3 Opportunities
5.5.3.1 Increase in Coronary Artery Disease
5.5.3.2 Moving Away from Dual Antiplatelet Therapy
5.5.4 Threats
5.5.4.1 Small Number of Companies Operating in the US and Japan
5.5.4.2 The Drug May Become More Important than the Stent
5.5.4.3 The DES Market is Still Emerging
6. Neurological Device Market
6.1 Neurological Devices: Market Overview
6.2 Neurological Device Market Forecast, 2010-2015
6.3 Neuromodulation Market Analysis and Forecast, 2010-2025
6.3.1 Neuromodulation Market Forecast, 2010-2025
6.3.2 SCS Market Forecast, 2010-2015
6.3.3 SCS Market Forecast, 2015-2025
6.3.4 DBS Market Forecast, 2010-2015
6.3.5 DBS Market Forecast, 2015-2025
6.3.6 VNS Market Forecast, 2010-2015
6.3.7 VNS market Forecast, 2015-2025
6.3.8 Other Neuromodulation Devices Forecast, 2010-2025
6.4 Neuromodulation Product Analysis by Company
6.4.1 Medtronic
6.4.2 St Jude Medical
6.4.3 Boston Scientific
6.4.4 Cyberonics
6.5 Neuromodulation Device Pipeline
6.5.1 CVRx
6.5.2 Apnex Medical
6.5.3 ImThera Medical
6.5.4 NeuroPace
6.5.5 Intelect Medical
6.5.6 Devices for Treating Obesity
6.5.6.1 EnteroMedics
6.5.6.2 IntraPace
6.5.6.3 MetaCure
6.6 SWOT Analysis of the Neuromodulation Device Industry, 2010-2025
6.6.1 Strengths
6.6.1.1 Neuromodulation Can Be Seen as Safer than Alternative Treatments
6.6.1.2 Neuromodulation as a Cost-Effective Treatment Option
6.6.1.3 Neuromodulation Often Means Less Medication
6.6.2 Weaknesses
6.6.2.1 Neuromodulation Mechanisms Are Not Well Understood
6.6.2.2 A Small Number of Large Companies Dominate the Market
6.6.2.3 Many Devices Are Failing in Clinical Trials
6.6.3 Opportunities
6.6.3.1 The Uses for Neuromodulation are Set to Expand
6.6.3.2 Neurological Disorders Will Increase in Prevalence
6.6.4 Threats
6.6.4.1 Parkinson's May Soon Be Treatable with Stem Cells
6.6.4.2 SCS Faces Competition from Other Treatment Options
7. Expert Opinion
7.1 Franck Fischer and Rebecca Kuhn, CEO and CFO, NeuroPace Inc.
7.1.1 NeuroPace's RNS Neuromodulation System for Epilepsy
7.1.2 The Neuromodulation and Epilepsy Markets
7.1.3 Public Perception and Understanding of Neuromodulation
7.1.4 Small Companies Surviving in the Industry
7.1.5 Educating Physicians about Neuromodulation
7.1.6 Neuromodulation's Role in Relation to Other Treatment Options
7.1.7 Recent Healthcare Reform in the US
7.1.8 Comparative Effectiveness Research
8. Conclusions
8.1 The Medical Device Industry, 2010-2025
8.1.1 Growth Will Be Driven by Emerging Markets
8.1.2 Personalised Medicine Offers Opportunities to the Industry
8.2 The Coronary Stent Market, 2010-2025
8.2.1 Innovation Will Drive Growth in the DES Market
8.2.2 DES May Be Challenged by Other Stenting Technologies
8.3 The Neuromodulation Market, 2010-2025
8.3.1 Expanding Uses to Drive Growth Beyond 2015
8.3.2 Other Treatment Options Could Threaten Growth
[Inhaltsverzeichnis ausblenden]
